Cardiovascular risks of atypical antipsychotic drug treatment

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 8, 2007, Pages 882-890

  Drici, Milou Daniel ^a,c   Priori, Silvia ^b  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b IRCCS   (Italy)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Antipsychotic drugs; Cardiac risk; Cardiovascular disease; Metabolic syndrome; Schizophrenia; Sudden cardiac death

Indexed keywords

ANTIARRHYTHMIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DIURETIC AGENT; ERYTHROMYCIN; HALOPERIDOL; KETOCONAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE;

BLOOD PRESSURE VARIABILITY; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG FATALITY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECG ABNORMALITY; FACE EDEMA; GLUCOSE INTOLERANCE; HEART ARRHYTHMIA; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTENSION; LEG EDEMA; METABOLIC DISORDER; MYOCARDITIS; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PERIORBITAL EDEMA; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULSE RATE; QT INTERVAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; ST SEGMENT DEPRESSION; SUDDEN DEATH; SYNCOPE; TACHYCARDIA; TORSADE DES POINTES; TRANSIENT ISCHEMIC ATTACK; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; ELECTROCARDIOGRAPHY; HUMANS; HYPOTENSION, ORTHOSTATIC; METABOLIC SYNDROME X; SCHIZOPHRENIA;

EID: 34548224606     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1424     Document Type: Review

References (75)

1. Hennekens C, Hennekens A, Hollar D, Casey D. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150(6): 1115-1121.
2. Wilk J, Marcus SC, West J, et al. Substance abuse and the management of medication non adherence in schizophrenia. J Nerv Ment Dis 2006; 194(6): 454-457.
3. Martinez JB, Moos DD, Dahlen LL. Droperidol's effect on QT interval. J Perianesth Nurs 2006; 21(2): 82-87.
4. Timell AM. Thioridazine: re-evaluating the risk/benefit equation. Ann Clin Psychiatry 2000; 12(3): 147-151.
5. http://agmed.sante.gouv.fr/htm/10/filcoprs/050507.htm. Access July 13, 2006.
6. Lindborg S, Beasley C, Alaka Y, Taylor C. Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Res 2003; 119: 113-123.
7. Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993; 163: 183-189.
8. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212-217.
9. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000; 45: 21-28.
10. IMS data, 2006.
11. Collaborative Working Group on Clinical Trials Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998; 59 (Suppl. 12): 17-22.
12. Drici M-D, Wang W-X, Liu X-K, et al. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 1998a; 18: 477-481.
13. Brown LA, Levin GM. Sertindole, a new atypical antipsychotic for the treatment of schizophrenia. Pharmacotherapy 1998; 18(1): 69-83.
14. Garver DL. Review of quetiapine side effects. J Clin Psychiatry 2000; 61 (Suppl. 8): 31-33; discussion 34-5.
15. George TP, Winther LC. Hypertension after initiation of clozapine. Am J Psychiatry 1996; 153(10): 1368-1369.
16. Ennis LM, Parker RM. Paradoxical hypertension associated with clozapine. Med J Aust 1997; 166(5): 278.
17. Goyal RS, Goyal SB. Symptomatic bradyarrhythmia secondary to risperidone. Am J Psychiatry 2003; 160(12): 2243.
18. Markowitz JS, DeVane CL, Boutton DW, Liston HL, Risch SC. Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine. J Clin Pharmacol 2002; 42(1): 104-106.
19. Alexander H, Glassman MD. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005; 66 (Suppl. 6): 5-10.
20. http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&nodeId= 742. Access on July 12th, 2006.
21. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drugs Saf 2000; 23: 215-228.
22. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316(7): 363-369.
23. Taylor D, Paton C, Kerwin R, et al. The South London and Maudsley NHS Trust 2003 Prescribing Guidelines (7th edn). Martin Dunitz: London; 2003.
24. Hunt N, Stern T. The association between intravenous haloperidol and Torsades de Pointes. Psychosomatics 1995; 36: 541-549.
25. Zareba W, Lin DA. Antipsychotic drugs and QT interval prolongation. Psychiatr Q 2003; 74(3): 291-306.
26. Feinstein RE. Cardiovascular effects of novel antipsychotic medications. Heart Dis 2002; 4: 184-190.
27. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-1782.
28. Lindstrom E, Farde L, Eberhard J, Haverkamp W. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neuropsychopharmacol 2005; 8(4): 615-629.
29. McGavin JK, Goa KL. Aripiprazole. CNS Drugs 2002; 16(11): 779-786; discussion 787-8.
30. Roden DM, Drici M-D. In Drug-Induced Sudden Death. Sudden Cardiac Death, Priori SG, Zipes DP (eds). Blackwell Publishing: Malden MS, USA, Oxford UK and Carlton, Australia, 2006; 177-189.
31. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341(12): 857-865.
32. Kober L, Bloch Thomsen PE, Moller M, et al. Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 2000; 356(9247): 2052-2058.
33. Vieweg WV, Schneider RK, Wood MA. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta Psychiatr Scand 2005; 112(4): 318-322.
34. Tei Y, Morita T, Inoue S, Miyata H. Torsades de pointes caused by a small dose of risperidone in a terminally ill cancer patient. Psychosomatics 2004; 45(5): 450-451.
35. O'Brien JM, Rockwood RP, Sub KI. Haloperidol-induced torsade de pointes. Ann Pharmacother 1999; 33(10): 1046-1050.
36. Brown LA, Levin GM. Sertindole, a new atypical antipsychotic for the treatment of schizophrenia. Pharmacotherapy 1998; 18(1): 69-83.
37. Eckardt L, Haverkamp W, Borggrefe M, Breithardt G. Experimental models of torsade de pointes. Cardiovasc Res 1998; 39: 178-193.
38. Eckardt L, Breithardt G, Haverkamp W. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther 2002; 300: 64-71.
39. Expert Panel on Detection and Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
40. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-419.
41. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-1214.
42. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
43. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-1529.
44. Walker M, Wannamethee G, Whincup PH, Shaper AG. Weight change and risk of heart attack in middle-aged British Men. Int J Epidemiol 1995; 24: 694-703.
45. FDA Patient Safety News. Warning about hyperglycemia and atypical antipsychotic drugs. Show #28, June 2004.
46. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502-508.
47. National Institutes of Health Consensus Development Panel on the Health Implications of Obesity. Health implications of obesity. National Institutes of Health Consensus Development Conference statement. Ann Int Med 1985; 103: 1073-1077.
48. Kawachi I. Physical and psychological consequences of weight gain. J Clin Psychiatry 1999; 60 (Suppl. 21): 5-9.
49. Hägg S, Lindblom Y, Mjörndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006; 21: 93-98.
50. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80(1): 19-32.
51. Stroup TS, McEvoy JP, Swartz MS, et al. The national institute of mental health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2006; 29: 15-31.
52. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
53. Drici M-D. Influence of gender on drug-acquired long QT syndrome. Eur Heart J Supplements 2001; 3 (Suppl. K): K41-K47.
54. Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001; 62 (Suppl. 7): 32-37.
55. Green AI, Patel JY, Goisman RM, et al. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 2000; 22: 224-235.
56. Allison DB, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696.
57. Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf 2001; 24: 59-73.
58. Lewis R, Bagnall AM, Leitner M. Sertindole for schizophrenia. Cochrane Database Syst Rev 2005; (3): CD001715.
59. http://www.fda.gov/medwatch/SAFETY/2004/apr_PI/Abilify_PI.pdf Access on July 12th, 2006.
60. Melkersson K, Dahl M-L. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004; 64: 701-723.
61. Hedenmalm K, Hagg S, Stahl M, et al. Glucose intolerance with atypical antipsychotics. Drug Saf 2002; 25: 1107-1116.
62. Griffiths J, Springuel P. Atypical antipsychotics: impaired glucose metabolism. Can Adverse Drug React News 2001; 11(4): 3-6.
63. Adverse Drug Reactions Advisory Committee (ADRAC). Atypical antipsychotics and hyperglycaemia. Aust Adverse Drug React Bull 2004; 23: 11-12.
64. Citrome LL, Jaffe AB. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother 2003; 37: 1849-1857.
65. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1-17.
66. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601.
67. Casey DE, Zorn SH. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 2001; 62 (Suppl. 7): 4-10.
68. Sowell MO, Mukhopadhyay N, Cavazzoni P, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 2002; 87: 2918-2923.
69. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21: 369-374.
70. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 (Suppl. 18): 27-35.
71. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001; 345(3): 224-225.
72. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drugs Saf 2000; 23: 215-228.
73. Hwang IP, Yang CH, Yu HC, Chang JW, Cheng CY, Tsai SJ. The efficacy and safety of risperidone for the treatment of geriatric psychosis. J Clin Psychopharmacol 2001; 21(6): 583-587.
74. Durst R, Raskin S, Katz G, Zislin J, Durst R. Pedal edema associated with clozapine use. Isr Med Assoc J 2000; 2(6): 485-486.
75. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005; 66(2): 183-194; quiz 147, 273-4.